

OBESITY TREATMENT AGENTS PRIOR AUTHORIZATION FORM (form effective 1/8/2024)

Prior authorization guidelines for **Obesity Treatment Agents** and **Quantity Limits/Daily Dose Limits** are available on the DHS Pharmacy Services website at https://www.dhs.pa.gov/providers/Pharmacy-Services/Pages/default.aspx.

		Dan engliser			
☐ New request ☐ Renewal request	# of pages:	Prescriber name:			
Name of office contact:		Specialty:	Specialty:		
Contact's phone number:		NPI:	State lic	ense #:	
LTC facility contact/phone:		Street address:	Street address:		
Beneficiary name:		City/state/zip:	City/state/zip:		
Beneficiary ID#:	DOB:	Phone:	Fax:		
	CLII	NICAL INFORMATION			
Drug requested:					
Strength & package size/quantity/refills:					
Additional strengths / quantity for each / ref	ills for each to allow	for <u>dose titration</u> :			
Directions:					
Diagnosis (submit documentation):			Dx code (required):	
For a non-preferred Obesity Treatment Agent, does the beneficiary have a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agents appropriate for the beneficiary's diagnosis or indication? Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.			□Yes □No	Submit documentation.	
Does the beneficiary have any contraindications to the requested medication?			□Yes □No	Submit documentation.	
ATTESTATION from the prescriber: Was beneficiary recently counseled about lifestyle changes and behavior modifications such as a healthy diet and increased physical activity?					
Compl	ete all sections th	nat apply to the beneficiary and this requ	iest.		

Complete all sections that apply to the beneficiary and this request.

Check all that apply and submit documentation for each item.



	IINI I IZ	AL requests
1.	The beneficiary is <u>18 years of age or older</u> :	
	Pre-treatment weight: Pre-tre	eatment BMI:
	☐ Has a BMI greater than or equal to 30 kg/m²	
	☐ Has a BMI greater than or equal 27 kg/m² and less than	n 30 kg/m ² and at least one of the following weight-related comorbidities:
	☐dyslipidemia	obstructive sleep apnea
	hypertension	prediabetes
	☐metabolic syndrome ☐other (list):	☐type 2 diabetes
	☐ Is a candidate for treatment based on degree of adiposi	ty, waist circumference, history of bariatric surgery, BMI exceptions for
	beneficiary's ethnicity, etc. and has at least one of the f	ollowing weight-related comorbidities:
	☐dyslipidemia	obstructive sleep apnea
	hypertension	☐ prediabetes
	☐metabolic syndrome ☐other (list):	☐type 2 diabetes
2.	The beneficiary is <u>less than 18 years of age</u> :	
	Pre-treatment BMI: Pre-tre	eatment BMI z-score:
	☐ Has a BMI in the 95 th percentile or greater standardized	for age and sex based on current CDC charts
3.	 ☐ Has a history of trial and failure of or a contraindication non-preferred) ☐ Has prescriber documentation explaining why Evekeo (☐ For a beneficiary with a history of substance depen ☐ Has results of a recent UDS for licit & illicit drugs w fentanyl, and tramadol) that is consistent with pres 	or an intolerance of all other Obesity Treatment Agents (preferred and amphetamine) is needed and a plan for tapering dency, abuse, or diversion: ith the potential for abuse (including specific testing for oxycodone,
1.	All requests: The dose of the requested medication is currently being The beneficiary is experiencing clinical benefit with the	y titrated
2.	The beneficiary is <u>18 years of age or older</u> :	
	Pre-treatment weight:	Current weight:
3.	The beneficiary is <u>less than 18 years of age</u> :	
	Pre-treatment BMI:	Current BMI:
	Pre-treatment BMI z-score:	Current BMI z-score:
4.	Request is for Evekeo (amphetamine) ODT/tablet:	



Office of Medical Assistance Programs Fee-for-Service, Pharmacy Division Phone 1-800-537-8862 Fax 1-866-327-0191

☐ Has prescriber documentation explaining why Evekeo (amphetamine) is needed and a plar	n for tapering (submit documentation)	
For a beneficiary with a history of substance dependency, abuse, or diversion:		
☐ Has results of a recent UDS for licit & illicit drugs with the potential for abuse (including specific testing for oxycodone,		
fentanyl, and tramadol) that is consistent with prescribed controlled substances		
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION T	O DHS - PHARMACY DIVISION	
PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION T Prescriber Signature:	O DHS – PHARMACY DIVISION Date:	

<u>Confidentiality Notice</u>: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.